Floatz logo

Zilovertamab Vedotin

Diffuse Large B-cell Lymphoma

Merck Sharp & Dohme LLCantibody_drug_conjugatePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
73/ 100

Competitive context

270 Active assets in the Diffuse Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Zilovertamab Vedotin is also rated in:

Richter transformationDormant
B
Indicative ·
60 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
B
Indicative ·
57 / 100
View asset →
Burkitt lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →